Long QT Syndrome Clinical Trial
Official title:
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Torsades de pointes (TdP) is a potentially fatal ventricular arrhythmia associated with corrected QT (QTc) interval prolongation. More than 50 commonly used drugs available on the US market may cause QTc interval prolongation and TdP. While TdP occurs more commonly in women, 33-45% of all cases of TdP have occurred in men. Older age is a risk factor for drug-induced TdP in men, possibly due to declining serum testosterone concentrations. Available evidence shows an inverse relationship between QTc intervals and serum testosterone concentrations. In addition, experimental data, including those from the investigators' laboratory, suggest that both exogenous testosterone or progesterone administration may be protective against prolongation of ventricular repolarization and TdP. Specific Aim: Establish the influence of transdermal testosterone administration and oral progesterone administration as preventive methods by which to diminish the degree of drug-induced QT interval prolongation in men 65 years of age or older. Hypothesis: Transdermal testosterone administration and oral progesterone administration both effectively attenuate drug-induced QT interval response in older men. To test this hypothesis, transdermal testosterone, oral progesterone or placebo will be administered in a 3-way crossover study to men 65 years of age or older. QTc interval response to low-dose ibutilide will be assessed. The primary endpoints will be Fridericia-corrected QT interval (QTF) response to ibutilide, in the presence and absence of testosterone, and in the presence or absence of progesterone: 1) Effect on pre-ibutilide QTF, 2) Effect on maximum post-ibutilide QTF, 3) Effect on % change in post-ibutilide QTF, and 2) Area under the QTF interval-time curves.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 | |
| Completed |
NCT01648205 -
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
|
Phase 2 | |
| Recruiting |
NCT06087367 -
Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
|
||
| Recruiting |
NCT04675788 -
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
|
Phase 4 | |
| Completed |
NCT05759962 -
Phase 1 Study of LQT-1213 in Healthy Adults
|
Phase 1 | |
| Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
| Terminated |
NCT02439645 -
A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
|
||
| Recruiting |
NCT00221832 -
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
|
N/A | |
| Completed |
NCT04706104 -
QT Measurement Techniques and Anesthesia Management
|
||
| Recruiting |
NCT04336644 -
Continuous Versus Intermittent cARdiac Electrical moNitorinG
|
N/A | |
| Recruiting |
NCT02814981 -
Hydroxyzine and Risk of Prolongation of QT Interval
|
N/A | |
| Completed |
NCT02425189 -
The Canadian National Long QT Syndrome Registry
|
||
| Completed |
NCT02876380 -
Prospective Identification of Long QT Syndrome in Fetal Life
|
||
| Completed |
NCT00399412 -
ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
|
N/A | |
| Completed |
NCT02441829 -
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
|
Phase 1 | |
| Completed |
NCT03182777 -
Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
|
N/A | |
| Completed |
NCT01849003 -
Study of the Effect of GS-6615 in Subjects With LQT-3
|
Phase 1 | |
| Completed |
NCT00316459 -
Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00292032 -
Registry of Unexplained Cardiac Arrest
|
||
| Recruiting |
NCT05348564 -
Comparing Direct vs Indirect Methods for Cascade Screening
|
N/A |